View More Recent Stories

Sep 11, 2024 02:32PM TD Cowen Reiterates Buy Rating on Regeneron Pharma (REGN)
Sep 11, 2024 07:01AM Regeneron (REGN): EYLEA HD Injection 8 mg Data at EURETINA Reinforce Long-term Durability, Sustained Fluid Control and Safety Profile
Sep 11, 2024 06:15AM Regeneron (REGN) Reports Dupixent Phase 3 Trial Confirmed Significant Improvements in Itch and Hives for Patients with CSU
Sep 9, 2024 05:00PM Regeneron (REGN): Libtayo Demonstrates Durable Survival Benefit at Five Years in Advanced Non-small Cell Lung Cancer
Sep 9, 2024 06:24AM Regeneron Pharma (REGN) PT Raised to $1,282 at RBC Capital
Aug 26, 2024 09:57AM TD Cowen Reiterates Buy Rating on Regeneron Pharma (REGN)
Aug 26, 2024 07:03AM Regeneron (REGN): Ordspono Approved in the European Union for the Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
Aug 23, 2024 08:35AM Regeneron Pharma (REGN) PT Raised to $1,242 at Piper Sandler
Aug 21, 2024 07:12AM Regeneron (REGN) Provides Update on Biologics License Application for Linvoseltamab
Aug 19, 2024 07:35AM TD Cowen Reiterates Buy Rating on Regeneron Pharma (REGN)
Aug 1, 2024 04:49PM Regeneron (REGN) Tops Q2 EPS by 95c
Jul 30, 2024 07:17AM RBC's biotech survey shows investors more bearish vs. last time
Jul 23, 2024 07:00AM Oppenheimer Upgrades argenx SE (ARGX) to Outperform
Jul 23, 2024 06:34AM Regeneron Pharma (REGN) PT Raised to $1,200 at TD Cowen
Jul 21, 2024 06:00AM 10 policies if Trump wins and stock implications: Jefferies
Jul 19, 2024 07:17AM Regeneron Pharma (REGN) PT Raised to $1,166 at Piper Sandler
Jul 12, 2024 11:21AM Regeneron Pharma (REGN) PT Raised to $1,250 at UBS
Jul 12, 2024 07:51AM BMO Capital Reiterates Outperform Rating on Regeneron Pharma (REGN)
Jul 9, 2024 07:00PM 2Q24 U.S. biotech earnings preview
Jul 3, 2024 07:43AM Pharma selloff overdone: JPMorgan
Jul 3, 2024 05:51AM Regeneron (REGN) Announces Dupixent Approved in the EU for COPD
Jun 28, 2024 07:17AM Regeneron (REGN): Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
Jun 25, 2024 07:20AM Regeneron Pharma (REGN) PT Raised to $1,170 at Argus
Jun 24, 2024 06:21AM RBC Capital Reiterates Outperform Rating on Regeneron Pharma (REGN)
Jun 14, 2024 07:40AM TD Cowen Reiterates Buy Rating on Regeneron Pharma (REGN)
Jun 12, 2024 06:18AM Regeneron Pharma (REGN) PT Raised to $1,229 at RBC Capital
Jun 11, 2024 07:01AM Regeneron (REGN): Kevzara Approved by FDA for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis (pJIA)
Apr 28, 2024 02:00PM Analyst explains why Eylea is so important to Regeneron (REGN) shares
View More Recent Stories